Inoculation with Ixchiq is authorized for people over 18 years of age. It is injected in one dose and contains an attenuated version of the virus.
USA approved a chikungunya vaccinethe first for this viral disease present in the region of America that spreads through the mosquito biteannounced the health authorities.
The vaccine of the group Valneva will be marketed under the name Ixchiq and is authorized for people over 18 yearswho are more exposed to the virus, reported the United States Food and Drug Administration (FDA) it’s a statement.
vaccines germany.jpeg
Chikungunya: symptoms, endemic areas and cases of infection
The most common symptoms of the infection are fever and joint painbut it can also cause rash. He chikungunya “is a emerging threat to global healthwith at least five million cases of infection” by the virus recorded during the last 15 years, reported the FDA.
The highest risk of infection is in tropical and subtropical regions of AfricaSoutheast Asia and parts of America where mosquitoes carrying the virus are endemic.
“Virus infection chikungunya May cause serious illnesses and long-term health problemsspecially in people of the Third Age and individuals with underlying medical conditions,” explained Peter Marksdirector of FDA Center for Biologics Evaluation and Research.
Puddler mosquito Aedes albifasciatus.jpg
Courtesy: redeangola
Chikungunya vaccine: dosage and its side effects
The vaccine is injected into a dose and contains an attenuated version of the virus chikungunya, a frequently used technique. They have already been carried out two clinical trials in North America with thousands of people and only two had to be hospitalizedreported the AFP agency.
The main side effects are headaches or muscle aches, fatigue and even nausea. In a few cases, more serious reactions were observed, the statement said.
Source: Ambito
